Biomedical Occupation or Discipline – Page 16

AbbVie Expands Immunology Pipeline with $200M Acquisition of Nimble Therapeutics

7 months ago talkbio0Tagged AbbVie, Autoimmune Diseases, IL23R gene, Immunology, Inhibitor, Nimble, Peptides, Psoriasis

AbbVie, Nimble Therapeutics, Immunology, Psoriasis, Autoimmune Diseases, IL23R Inhibitor, Peptide Therapeutics

Gilead Sciences Appoints Dietmar Berger as Chief Medical Officer to Spearhead R&D Revamp

7 months ago talkbio0Tagged Biotechnology, Chief Medical Officer, Dietmar Berger, Drug Industry, Gilead Sciences, R&D, reSET (device)

Gilead Sciences, Dietmar Berger, Chief Medical Officer, R&D Reset, Biotechnology, Pharmaceutical Industry

Pleno Secures $25M Funding for Commercial Launch, Appoints New CEO from Illumina

7 months ago talkbio0Tagged CEO, commercial, Illumina, launch, Multiomics, Pleno

Pleno, multiomics, funding, commercial launch, new CEO, Illumina

Acelyrin Reassesses Flagship Immunology Asset Izokibep Following Multiple Clinical Trial Setbacks

7 months ago talkbio0Tagged Acelyrin, Arthritis, Psoriatic, biotech, Clinical Trials, Failure (biologic function), Hidradenitis, Immunology, IPO, Izokibep, suppurativa

Acelyrin, Izokibep, Clinical Trial Failure, Immunology, Hidradenitis Suppurativa, Psoriatic Arthritis, Biotech IPO

Negev Labs Unveils Next-Gen Psychedelic Therapies with Non-Hallucinogenic Neuroplastogens

7 months ago talkbio0Tagged Biotechnology, Builder, Hallucinogens, Laboratory test finding, mental health, Negev, neuroplastogens, non-hallucinogenic, psychedelic therapies

Negev Labs, neuroplastogens, psychedelic therapies, non-hallucinogenic psychedelics, mental health treatments, biotechnology company builder

nChroma Bio Emerges from Chroma Medicine and Nvelop Therapeutics Merger, Secures $75 Million to Advance Genetic Medicines

7 months ago talkbio0Tagged Biotechnology, Chroma Medicine, epigenetic editing, financing characteristics, genetic medicines, Merger, nChroma, Non-Viral Delivery

nChroma Bio, Chroma Medicine, Nvelop Therapeutics, Genetic Medicines, Epigenetic Editing, Non-Viral Delivery, Biotechnology, Merger, Financing

uniQure Secures FDA Agreement on Accelerated Approval Pathway for Huntington’s Disease Gene Therapy AMT-130

7 months ago talkbio0Tagged Accelerated, AMT-130, Approved, cUHDRS, gene therapy, Huntington 's disease, NEFL gene, NfL, Regenerative Medicine, RMAT, UniQure, United States Food and Drug Administration

uniQure, FDA, Accelerated Approval, Huntington’s Disease, Gene Therapy, AMT-130, cUHDRS, Neurofilament Light Chain (NfL), Regenerative Medicine Advanced Therapy (RMAT)

Relmada Therapeutics Reassesses Strategy Following Discontinuation of Two Phase 3 Trials for REL-1017

7 months ago talkbio0Tagged Clinical Trials, Drug Development, MDD, Phase 3 trials, REL-1017, Relmada, Strategic Options, Unipolar Depression

Relmada Therapeutics, REL-1017, Phase 3 trials, Major Depressive Disorder (MDD), strategic options, clinical trials, drug development

BIOSECURE Act Excluded from US Defense Bill, Offering Reprieve to Chinese Biotechs

7 months ago talkbio0Tagged BIOSECURE, Biotechnology, biotechs, Chinese Language, National Security, U.S.

BIOSECURE Act, Chinese biotechs, US defense bill, biotechnology supply chains, national security concerns

GSK Partners with Muna Therapeutics to Advance Alzheimer’s Treatment Research

7 months ago talkbio0Tagged Alzheimer 's disease, Collaboration, drug research, genetic code analysis, Muna, Neurodegenerative Disorders, Neuroscience discipline, SmithKline Beecham

GSK, Muna Therapeutics, Alzheimer’s disease, neurodegenerative diseases, drug research, genetic code analysis, neuroscience, collaboration.